Page 6 - U11248 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from U11248. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In U11248 Today - Breaking & Trending Today

ADC Toxicities: The Price You Pay for Efficacy

Understanding the toxicities associated with antibody-drug conjugates could help oncologists develop strategies to diminish adverse events that arise during treatment with these powerful agents ....

United States , Dana Farber Cancer Institute , Paolo Tarantino , Aditya Bardia , Massachusetts General Hospital , Biologic Therapy , Cancer Treatment Related Toxicity , Monoclonal Antibody , Antibody Drug Conjugates Adcs , Antineoplastic Drug , Nti Cancer Agents , Breast Cancer , Alignant Breast Neoplasm , Drug Development , Humanized Monoclonal Antibody ,

FDA Approves Bosutinib for Children With CML

The agency approved the tyrosine kinase inhibitor for pediatric patients with chronic phase Ph+ chronic myelogenous leukemia that is newly diagnosed or resistant or intolerant to prior therapy. ....

United States , Drug Administration , Chronic Myelogenous Leukemia , Pain Management , Pain Management , Tyrosine Kinase Inhibitor , Biologic Therapy , Tyrosine Kinase , Liver Enzymes , Liver Studies , Abdominal Pain , White Blood Cell Count , Leukocyte Count , Tbc Count , Hite Count ,

Could Your Patients Benefit? New Trials in Lung Cancer

Several trials in lung cancer have opened their doors recently perhaps one of your patients could benefit. ....

United States , Research Center , National Cancer Institute , Gabrail Cancer , Fast Track Designation , Lung Cancer , Ung Carcinoma , Ancer Lung , Non Small Cell Lung Cancer , Small Cell Lung Cancer , Alignant Neoplasia , Biologic Therapy , Intravenous Iv , Tyrosine Kinase Inhibitor ,

Osimertinib Plus Chemo Ups PFS, Toxicity in First Line

Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non-small cell lung cancer, new interim data show, but experts have raised concerns about toxicity. ....

Dana Farber Cancer Institute , United States , New York , Long Wu , Mohana Roy , Christian Rolfo , Icahn School Of Medicine At Mount Sinai , Guangdong Lung Cancer Institute , Lowe Center , Thoracic Oncology , Guangdong Provincial People , Icahn School , Mount Sinai , Lung Cancer , Ung Carcinoma , Ancer Lung , Small Molecule Inhibitor , Non Small Cell Lung Cancer , Malignant Secondary Lung Neoplasm , Etastasis Lung , Antineoplastic Drug , Nti Cancer Agents , Biologic Therapy , Alignant Neoplasia , Tyrosine Kinase Inhi ,

Nilotinib Linked to Metabolic Syndrome and CVD in CML

Investigators suggest using other TKIs in patients with preexisting diabetes and hyperlipidemia. ....

Chang Gung Memorial Hospital , Taoyuan Xian , Jiayi Shi , Republic Of China , Taiwan General , Chang Gung Medical Foundation , Cih En Huang , Chronic Myelogenous Leukemia , Small Molecule Inhibitor , Cardiometabolic Risk , Ipid Management , Tyrosine Kinase Inhibitor , Metabolic Syndrome , Biologic Therapy , Antineoplastic Drug , Nti Cancer Agents ,